Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms. / Holmager, Pernille; Langer, Seppo W; Federspiel, Birgitte; Willemoe, Gro Linno; Garbyal, Rajendra Singh; Melchior, Linea; Klose, Marianne; Kjaer, Andreas; Hansen, Carsten Palnaes; Andreassen, Mikkel; Knigge, Ulrich.

In: Journal of Neuroendocrinology, Vol. 33, No. 9, e13018, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Holmager, P, Langer, SW, Federspiel, B, Willemoe, GL, Garbyal, RS, Melchior, L, Klose, M, Kjaer, A, Hansen, CP, Andreassen, M & Knigge, U 2021, 'Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms', Journal of Neuroendocrinology, vol. 33, no. 9, e13018. https://doi.org/10.1111/jne.13018

APA

Holmager, P., Langer, S. W., Federspiel, B., Willemoe, G. L., Garbyal, R. S., Melchior, L., Klose, M., Kjaer, A., Hansen, C. P., Andreassen, M., & Knigge, U. (2021). Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms. Journal of Neuroendocrinology, 33(9), [e13018]. https://doi.org/10.1111/jne.13018

Vancouver

Holmager P, Langer SW, Federspiel B, Willemoe GL, Garbyal RS, Melchior L et al. Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms. Journal of Neuroendocrinology. 2021;33(9). e13018. https://doi.org/10.1111/jne.13018

Author

Holmager, Pernille ; Langer, Seppo W ; Federspiel, Birgitte ; Willemoe, Gro Linno ; Garbyal, Rajendra Singh ; Melchior, Linea ; Klose, Marianne ; Kjaer, Andreas ; Hansen, Carsten Palnaes ; Andreassen, Mikkel ; Knigge, Ulrich. / Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms. In: Journal of Neuroendocrinology. 2021 ; Vol. 33, No. 9.

Bibtex

@article{5a78c8f1e6254a9c8d7415e28e413d92,
title = "Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms",
abstract = "An increase in the Ki-67 index in neuroendocrine neoplasms over time in relation to prognosis has scarcely been investigated. We aimed to assess whether the Ki-67 index changed over time and also whether a change influenced prognosis. Second, we investigated the difference in the Ki-67 index between primary tumour and metastases. From 1 January 1995 to 31 December 2019, 108 consecutive patients with gastroenteropancreatic tumours were included. Patients were followed with regard to an increase in the Ki-67 index and all-cause mortality. Ki-67 determination of the primary tumour at diagnosis and at the time of radiological progression, including developed metastases, was performed. A significant increase in the Ki-67 index was defined as a doubling of the value at disease progression compared to the value at diagnosis. In addition, in 14 patients, the Ki-67 index of the primary tumour and present metastases at the time of diagnosis was investigated. At diagnosis, there were no differences in the Ki-67 index between primary tumours and metastases (P = .41). Sixty-five patients had a doubling of the Ki-67 index. The median Ki-67 index at the time of progression 17% (1%-90%) vs 5% (1%-60%) at the time of diagnosis (P = .006). A doubling of the Ki-67 index was independently associated with all-cause mortality (hazard ratio = 2.7 [1.3-6.3], P = 0.02), after adjustment for relevant co-variables including the Ki-67 index at baseline. Doubling of the Ki-67 index at the time of disease progression was associated with a significantly higher risk of all-cause mortality. We recommend that a Ki-67 index is obtained whenever disease progression is recorded by demonstrated progression because it may have impact on the choice of treatment.",
author = "Pernille Holmager and Langer, {Seppo W} and Birgitte Federspiel and Willemoe, {Gro Linno} and Garbyal, {Rajendra Singh} and Linea Melchior and Marianne Klose and Andreas Kjaer and Hansen, {Carsten Palnaes} and Mikkel Andreassen and Ulrich Knigge",
note = "{\textcopyright} 2021 British Society for Neuroendocrinology.",
year = "2021",
doi = "10.1111/jne.13018",
language = "English",
volume = "33",
journal = "Journal of Neuroendocrinology",
issn = "0953-8194",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms

AU - Holmager, Pernille

AU - Langer, Seppo W

AU - Federspiel, Birgitte

AU - Willemoe, Gro Linno

AU - Garbyal, Rajendra Singh

AU - Melchior, Linea

AU - Klose, Marianne

AU - Kjaer, Andreas

AU - Hansen, Carsten Palnaes

AU - Andreassen, Mikkel

AU - Knigge, Ulrich

N1 - © 2021 British Society for Neuroendocrinology.

PY - 2021

Y1 - 2021

N2 - An increase in the Ki-67 index in neuroendocrine neoplasms over time in relation to prognosis has scarcely been investigated. We aimed to assess whether the Ki-67 index changed over time and also whether a change influenced prognosis. Second, we investigated the difference in the Ki-67 index between primary tumour and metastases. From 1 January 1995 to 31 December 2019, 108 consecutive patients with gastroenteropancreatic tumours were included. Patients were followed with regard to an increase in the Ki-67 index and all-cause mortality. Ki-67 determination of the primary tumour at diagnosis and at the time of radiological progression, including developed metastases, was performed. A significant increase in the Ki-67 index was defined as a doubling of the value at disease progression compared to the value at diagnosis. In addition, in 14 patients, the Ki-67 index of the primary tumour and present metastases at the time of diagnosis was investigated. At diagnosis, there were no differences in the Ki-67 index between primary tumours and metastases (P = .41). Sixty-five patients had a doubling of the Ki-67 index. The median Ki-67 index at the time of progression 17% (1%-90%) vs 5% (1%-60%) at the time of diagnosis (P = .006). A doubling of the Ki-67 index was independently associated with all-cause mortality (hazard ratio = 2.7 [1.3-6.3], P = 0.02), after adjustment for relevant co-variables including the Ki-67 index at baseline. Doubling of the Ki-67 index at the time of disease progression was associated with a significantly higher risk of all-cause mortality. We recommend that a Ki-67 index is obtained whenever disease progression is recorded by demonstrated progression because it may have impact on the choice of treatment.

AB - An increase in the Ki-67 index in neuroendocrine neoplasms over time in relation to prognosis has scarcely been investigated. We aimed to assess whether the Ki-67 index changed over time and also whether a change influenced prognosis. Second, we investigated the difference in the Ki-67 index between primary tumour and metastases. From 1 January 1995 to 31 December 2019, 108 consecutive patients with gastroenteropancreatic tumours were included. Patients were followed with regard to an increase in the Ki-67 index and all-cause mortality. Ki-67 determination of the primary tumour at diagnosis and at the time of radiological progression, including developed metastases, was performed. A significant increase in the Ki-67 index was defined as a doubling of the value at disease progression compared to the value at diagnosis. In addition, in 14 patients, the Ki-67 index of the primary tumour and present metastases at the time of diagnosis was investigated. At diagnosis, there were no differences in the Ki-67 index between primary tumours and metastases (P = .41). Sixty-five patients had a doubling of the Ki-67 index. The median Ki-67 index at the time of progression 17% (1%-90%) vs 5% (1%-60%) at the time of diagnosis (P = .006). A doubling of the Ki-67 index was independently associated with all-cause mortality (hazard ratio = 2.7 [1.3-6.3], P = 0.02), after adjustment for relevant co-variables including the Ki-67 index at baseline. Doubling of the Ki-67 index at the time of disease progression was associated with a significantly higher risk of all-cause mortality. We recommend that a Ki-67 index is obtained whenever disease progression is recorded by demonstrated progression because it may have impact on the choice of treatment.

U2 - 10.1111/jne.13018

DO - 10.1111/jne.13018

M3 - Journal article

C2 - 34414612

VL - 33

JO - Journal of Neuroendocrinology

JF - Journal of Neuroendocrinology

SN - 0953-8194

IS - 9

M1 - e13018

ER -

ID: 276655690